Nicholas Hornstein: Cholangiocarcinoma patients post gemcitabine based treatment by Arndt Vogel et al

Nicholas Hornstein, Oncology Fellow at MD Anderson Cancer Center, shared a post on X:

“Phase 2 Trial
100 Cholangiocarcinoma patients post gemcitabine based treatment
5-FU + nal-IRI vs 5-FU
DFS 2.6 vs 2.3 months; negative trial

2 drugs vs 1 trial design raise question of underlying efficacy of nal-IRI in cholangiocarcinoma!”

Read further.
Source: Nicholas Hornstein/X